Please provide your email address to receive an email when new articles are posted on . High FeNO levels indicate exacerbation and lung function risks. Most patients with high FeNO levels also had ...

Mild asthma could be better treated with the recent approval of the combination of albuterol/budesonide. The recent approval of albuterol/budesonide could change the way that mild asthma is treated in ...

In many patients, annual short-acting beta2-agonist prescription fulfillment is indicative of uncontrolled disease and increased incidence of exacerbations. Credit: Getty Images. Short-acting beta ...

Although approved for use among patients with severe or refractory asthma, few studies have investigated its effectiveness among patients with comorbid mild to moderate asthma and chronic ...

MISSISSAUGA, ON, Sept. 30, 2019 /CNW/ - AstraZeneca Canada announced today that Health Canada has approved the expanded use of Symbicort ® Turbuhaler ® (budesonide ...

Please provide your email address to receive an email when new articles are posted on . Patients with mild asthma are still at risk for severe exacerbations, which can impact their quality of life.

—appear to gain adequate relief by inhaling anti-inflammatory steroids only during periods of bad symptoms, rather than daily as current guidelines recommend, a new study shows. Symptoms of mild, ...

Researchers identify master regulator genes of asthma, provide new path forward in the study of asthma and the development of novel therapies. Bottom Line: Identification of these master regulator ...

Among patients with mild to moderate COVID-19, the asthma drug montelukast (Singulair) did not reduce duration of symptoms, results of the randomized controlled ACTIV-6 trial showed. After receiving ...